RESTON, Va.--(BUSINESS WIRE)-- #BetterWithBowman--Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, announced it will participate in three investor conferences in May: BofA Securities Industrials, Transportation & Airlines Key Leaders Conference, held May 13-15 in New York, NY 25th Annual B. Riley Securities Investor Conference, held May 22-23 in Beverly Hills, CA 22nd Annual Craig-Hallum Institutional Investor Conference, held May 28 in Minneapolis, MN A.

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the …

CINCINNATI, April 29, 2025 (GLOBE NEWSWIRE) -- Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen weeks ended March 29, 2025.

– ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces today it will showcase its ZenaDrone 1000 and IQ series drones as an exhibitor at several prominent upcoming US defense and technology conferences starting this week. These events will be an important opportunity to engage one-on-one with potential customers, key stakeholders, and industry leaders across the US military and government sectors as well as in the mining sector.

NEW YORK--(BUSINESS WIRE)--Granite Point Mortgage Trust Inc. Announces Dates for First Quarter 2025 Earnings Release and Conference Call and Provides Business Update.

MIDLAND, Texas--(BUSINESS WIRE)--New Era Helium, Inc. (Nasdaq: NEHC) (“NEH” or the “Company”), an exploration and production (E&P) company sourcing helium from natural gas reserves in the Permian Basin, today announced it will commence its infrastructure buildout within the Pecos Slope Field within the next two weeks as it has secured approval for approximately 120 miles of Rights-of-Way (ROW) in collaboration with the U.S. Department of the Interior's Bureau of Land Management (BLM) Pecos.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID:.

BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country and FAU release 2025 nursing study, revealing high stress, burnout, and staffing shortages impacting nurses nationwide.

SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care,.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

GREENVILLE, S.C.--(BUSINESS WIRE)---- $WRLD--World Acceptance Corporation (NASDAQ: WRLD) today reported financial results for its fourth quarter of fiscal 2025. Fourth fiscal quarter highlights During its fourth fiscal quarter, World Acceptance Corporation achieved improved earnings driven by an increase in our tax preparation revenue. The quarter also benefited from a partial forfeiture of our performance-based restricted shares granted in 2018 that had a $16.35 earnings per share (EPS) performance targ.

MADISON, N.J. , April 29, 2025 /PRNewswire/ -- Anywhere Real Estate Inc. (NYSE: HOUS) ("Anywhere" or the "Company"), a global leader in residential real estate services, today reported financial results for the first quarter ended March 31, 2025.

NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Skyworks Solutions, Inc. (NASDAQ:SWKS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/skyworks-solutions-inc-lawsuit-submission-form?prid=145939&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=145940&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your enCore Energy Corp. (NASDAQ:EU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/encore-energy-corp-lawsuit-submission-form?prid=145931&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=145932&wire=1 or contact Joseph E. Levi, Esq.

Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today mailed a letter to its stockholders in connection with its 2025 Annual Meeting of Stockholders ("Annual Meeting") urging stockholders to vote the GOLD proxy card "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun.

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention …